Abstract
Network
pharmacology
plays
a
pivotal
role
in
systems
biology,
bridging
the
gap
between
traditional
Chinese
medicine
(TCM)
theory
and
contemporary
pharmacological
research.
enables
researchers
to
construct
multilayered
networks
that
systematically
elucidate
TCM’s
multi-component,
multi-target
mechanisms
of
action.
This
review
summarizes
key
databases
commonly
used
network
pharmacology,
including
those
focused
on
herbs,
components,
diseases,
dedicated
platforms
for
analysis.
Additionally,
we
explore
growing
use
TCM,
citing
literature
from
Web
Science,
PubMed,
CNKI
over
past
two
decades
with
keywords
like
“network
pharmacology”,
“TCM
“herb
pharmacology”.
The
application
TCM
is
widespread,
covering
areas
such
as
identifying
material
basis
efficacy,
unraveling
action,
evaluating
toxicity,
safety,
novel
drug
development.
However,
challenges
remain,
lack
standardized
data
collection
across
insufficient
consideration
processed
herbs
Questions
also
persist
regarding
reliability
study
outcomes.
aims
offer
valuable
insights
reference
points
guide
future
research
precision
pharmacology.
Pharmaceutical Biology,
Год журнала:
2025,
Номер
63(1), С. 27 - 41
Опубликована: Янв. 2, 2025
Context
Recent
research
has
revealed
significant
advancements
in
the
field
of
traditional
Chinese
medicine
(TCM)
for
skin
diseases.
However,
there
is
a
lack
visualization
analysis
within
this
domain.
Frontiers in Cardiovascular Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Фев. 13, 2025
Background
Tongmai
Yangxin
Pills
(TMYXP)
is
a
well-known
traditional
Chinese
medicine
compound
to
treat
coronary
heart
disease
(CHD).
Aging
key
immutable
independent
risk
factor
for
CHD.
Currently,
there
are
few
gene
expression
profiles
of
patients
treated
with
(TCM)
or
TCM
compound.
However,
the
chemical
composition
and
underlying
mechanisms
TMYXP
against
elderly
CHD
need
be
elucidated.
Objective
Exploring
mechanism
in
treating
based
on
human
profiles,
find
pharmacodynamic
ingredients
plasma
pharmacochemistry
network
pharmacology.
Methods
A
strength
this
study
use
pharmacology
analysis
before
after
treatment.
This
focused
peripheral
blood
mononuclear
cell
samples
from
6
over
60
years
old
(GSE142008).
total
40
components
identified
by
UPLC/Q-TOF-MS
method
SD
rats.
Then,
we
collected
literature-validated
component
targets
further
analysis.
Results
All
exhibited
non-toxic
properties.
By
retrieving
validated
components's
targets,
15
correspond
4,789
targets.
Genistein,
emodin,
isoliquiritigenin,
glycyrrhizic
acid,
gallic
verbascoside,
calycosin,
rhein,
formononetin
ephedrine
were
most
potential
anti-CHD
TMYXP.
The
above
10
mainly
regulate
hub
genes
CASP3,
TGFB1,
PTGS2,
CXCL8,
FAS
JAK2
,
mediating
multiple
exerts
effects
TNF
signaling
pathway,
PI3K-Akt
p53
MAPK
lipid
atherosclerosis,
NOD-like
receptor
diabetic
cardiomyopathy
cytokine-cytokine
interaction.
We
used
molecular
docking
technology
verify
direct
interaction
its
target
Conclusion
builds
bridge
connecting
confirmed
clinical
efficacy,
identifies
series
lead
compounds,
analyzes
their
possible
research
strategy
has
promote
modernization
transformation
drug
development.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 15, 2025
Tannic
acid
(TA)
is
the
primary
bioactive
component
in
gallnut
(Galla
chinensis)
and
has
exhibited
anticancer
effects.
However,
mechanism
of
its
anti-cancer
activity
nasopharyngeal
carcinoma
(NPC)
remains
unclear.
This
research
aims
to
explore
underlying
TA
treatment
cancer
using
network
pharmacology,
molecular
docking
experimental
validation.
Firstly,
targets
NPC
were
predicted
collected
through
databases,
intersection
identified.
Subsequently,
protein-protein
interaction
(PPI)
analysis,
Gene
Ontology
(GO)
enrichment,
Kyoto
Encyclopedia
Genes
Genomes
(KEGG)
pathway
enrichment
dynamics
(MD)
simulation
conducted
uncover
potential
mechanisms
NPC.
Finally,
vitro
experiments
utilized
verify
with
The
results
pharmacology
revealed
42
between
NPC-related
TA-related
targets.
phosphoinositide
3-kinase
(PI3K)/protein
kinase
B
(AKT)
signaling
was
identified
as
main
target
against
Additionally,
MD
confirmed
closely
binding
affinities
AKT1.
Furthermore,
demonstrated
that
exerts
by
targeting
PI3K/AKT
pathway,
leading
suppression
cell
proliferation.
a
promising
therapeutic
candidate
for
pathway.
These
provide
insights
into
clinical
application
TA,
particularly
when
considered
combination
other
modalities.
Drug Design Development and Therapy,
Год журнала:
2025,
Номер
Volume 19, С. 1083 - 1103
Опубликована: Фев. 1, 2025
To
investigate
the
effects
and
underlying
mechanisms
of
indirubin
in
treating
ALL
using
network
pharmacology
experimental
validation.
Potential
targets
indirubin-
ALL-related
genes
were
identified
public
databases.
Core
filtered
through
protein-protein
interaction
analysis
Cytoscape.
Gene
Ontology
(GO)
Kyoto
Encyclopedia
Genes
Genomes
(KEGG)
pathway
enrichment
analyses
conducted
to
explore
potential
against
ALL.
Drug-disease-functional
annotation-signaling
maps
constructed.
Molecular
docking
between
core
proteins
was
performed
AutoDock
Vina
software.
Finally,
both
vitro
vivo
experiments
validate
these
findings.
PPI
eight
ALL:
AKT1,
CASP3,
mammalian
target
rapamycin.
GO
KEGG
suggested
that
mechanism
action
involves
multiple
biological
functions
signaling
pathways,
with
PI3K-AKT
likely
playing
a
central
role.
findings
further
confirmed
strong
binding
affinity
for
targets.
Both
demonstrated
inhibited
cell
proliferation
induced
cycle
arrest
apoptosis;
may
involve
pathway.
The
pharmacology,
as
well
validation
elucidated,
offering
new
insights
therapeutic
avenues
treatment
